Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone DDI with Rifampin in Healthy Subjects
NCT03258372Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Aug 2017
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of mifepristone in Cushing's syndrome (2 cohorts), sponsored by Corcept Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) of Mifepristone at 18 days, Area Under the Curve to Last Measurable Concentration (AUC0-tz) of Mifepristone at 18 days and 1 more. Started Aug 2017; status: completed.
02
Drugs
mifepristone
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT03258372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258372.